These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25772215)

  • 1. Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.
    Ganesh T
    Expert Opin Ther Pat; 2015 Jul; 25(7):837-44. PubMed ID: 25772215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization studies of cinnamic amide EP2 antagonists.
    Ganesh T; Jiang J; Yang MS; Dingledine R
    J Med Chem; 2014 May; 57(10):4173-84. PubMed ID: 24773616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.
    Ganesh T; Banik A; Dingledine R; Wang W; Amaradhi R
    Mol Pharm; 2018 Dec; 15(12):5809-5817. PubMed ID: 30398879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of second generation EP2 antagonists with high selectivity.
    Ganesh T; Jiang J; Dingledine R
    Eur J Med Chem; 2014 Jul; 82():521-35. PubMed ID: 24937185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.
    Jiang J; Dingledine R
    Trends Pharmacol Sci; 2013 Jul; 34(7):413-23. PubMed ID: 23796953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.
    Jiang J; Yu Y; Kinjo ER; Du Y; Nguyen HP; Dingledine R
    Neuropharmacology; 2019 May; 149():149-160. PubMed ID: 30763657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells.
    Kay LJ; Gilbert M; Pullen N; Skerratt S; Farrington J; Seward EP; Peachell PT
    Clin Exp Allergy; 2013 Jul; 43(7):741-51. PubMed ID: 23786281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models.
    Amaradhi R; Banik A; Mohammed S; Patro V; Rojas A; Wang W; Motati DR; Dingledine R; Ganesh T
    J Med Chem; 2020 Feb; 63(3):1032-1050. PubMed ID: 31904232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.
    Jiang J; Ganesh T; Du Y; Quan Y; Serrano G; Qui M; Speigel I; Rojas A; Lelutiu N; Dingledine R
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3149-54. PubMed ID: 22323596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).
    Flesch D; Merk D; Lamers C; Schubert-Zsilavecz M
    Expert Opin Ther Pat; 2013 Feb; 23(2):233-67. PubMed ID: 23289354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
    Jiang J; Yang MS; Quan Y; Gueorguieva P; Ganesh T; Dingledine R
    Neurobiol Dis; 2015 Apr; 76():126-136. PubMed ID: 25600211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.
    Jiang J; Dingledine R
    J Pharmacol Exp Ther; 2013 Feb; 344(2):360-7. PubMed ID: 23192657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of prostaglandin E(2) on the migration of nasal fibroblasts.
    Shin JM; Park IH; Moon YM; Hong SM; Cho JS; Um JY; Lee HM
    Am J Rhinol Allergy; 2014; 28(3):e120-4. PubMed ID: 24980222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation.
    Takahashi T; Uehara H; Ogawa H; Umemoto H; Bando Y; Izumi K
    Oncotarget; 2015 Mar; 6(7):4829-44. PubMed ID: 25638159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
    Meja KK; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus.
    Nagib MM; Yu Y; Jiang J
    Pharmacol Ther; 2020 May; 209():107504. PubMed ID: 32088247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.
    Liang X; Wang Q; Shi J; Lokteva L; Breyer RM; Montine TJ; Andreasson K
    Ann Neurol; 2008 Sep; 64(3):304-14. PubMed ID: 18825663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.
    Parga JA; García-Garrote M; Martínez S; Raya Á; Labandeira-García JL; Rodríguez-Pallares J
    Mol Neurobiol; 2018 Jun; 55(6):4763-4776. PubMed ID: 28717970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.
    Sluter MN; Hou R; Li L; Yasmen N; Yu Y; Liu J; Jiang J
    J Med Chem; 2021 Aug; 64(16):11816-11836. PubMed ID: 34352171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes.
    Aso H; Ito S; Mori A; Suganuma N; Morioka M; Takahara N; Kondo M; Hasegawa Y
    Am J Respir Cell Mol Biol; 2013 Mar; 48(3):322-9. PubMed ID: 23221043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.